ID: MRFR/HC/8332-HCR | February 2021 | Region: Global | 153 pages
Global Vasomotor Symptoms Market is anticipated to hold a value of USD 8,189 Million till 2027 and is expected to register a CAGR of 7.27% during the assessment period of 2020 to 2027.
The increasing number of menopausal women demands the treatment for hot flashes and vaginal dryness. In the US, approximately 1.3 million women become menopausal each year. With such increased statistics, there is a huge demand for treatment options for vasomotor symptoms of menopause. Also, the companies operating in the market are focused on research and development for the production of a therapy that is completely harmless without any side-effects.
The companies operating in the vasomotor symptoms market are focused on receiving approvals from regulatory authorities to create a competitive edge over the products from their competitors. Also, established players are investing in clinical trials for the differentiation of products. Such initiatives promise an enormous level of growth in the market.
By Therapy Type
By Distribution Channel
|Market Size||2027: USD 8,189 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Therapy Type and Distribution Channel|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Allergan (Ireland), Pfizer Inc. (US), Eli Lily and Company (US), Novartis AG (Switzerland), Emcure Pharmaceuticals Ltd (India), Merck & Co., Inc. (US), TherapeuticsMD, Inc. (US), Mithra Pharmaceuticals (Belgium), Novo Nordisk A/S (Denmark), Procter & Gamble (US), EndoCeutics, Inc. (Canada), Amag Pharmaceuticals (US), and Teva Pharmaceuticals (Israel).|
|Key Market Opportunities||Rise in the Number of Companies investing in clinical trial candidates and research and development acts as a major contributor to the growth of the Vasomotor Symptoms Market.|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Global Vasomotor Symptoms Market is estimated to hold a value of USD 8,189 million by the end of 2027.
Global Vasomotor Symptoms Market is projected to expand at a CAGR of 7.27% by the end of 2027.
The increasing awareness created by medical professionals and major players about the benefits of hormonal therapies is estimated to escalate the global vasomotor symptoms market.
As per the research by MRFR, the Americas are anticipated to dominate the global vasomotor symptoms market.
The key players of the global vasomotor symptoms market are Allergan (Ireland), Amag Pharmaceuticals (US), EndoCeutics, Inc. (Canada), Procter & Gamble (US), TherapeuticsMD, Inc. (US), Teva Pharmaceuticals (Israel), Pfizer Inc. (US), Novo Nordisk A/S (Denmark), Novartis AG (Switzerland), Mithra Pharmaceuticals (Belgium), Merck & Co., Inc. (the US), Emcure Pharmaceuticals Ltd (India), and Eli Lily and Company (US).
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.